Loading market dashboard
Fulcrum Therapeutics, Inc.
FULCHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
The heavy selling pressure might have exhausted for Fulcrum Therapeutics (FULC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Fulcrum Therapeutics, Inc. stock lost roughly half its value in a single session after the company disclosed FDA safety concerns that forced discontinuation of its lead sickle-cell candidate Fulcrum Therapeutics, Inc. stock lost roughly half its value in a single session after the company disclosed FDA safety concerns that forced discontinuation of its lead sickle-cell candidate
NEW YORK--(BUSINESS WIRE)--Shareholders of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) saw the stock plunged roughly 50% on June 1, 2026, following disclosure of an FDA safety concerns related to the PRC2 inhibitor drug class. Those who lost money on FULC are encouraged to submit their information immediately. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. The single-session collapse followed Fulcrum's June 1, 2026 Form 8-K, which.
Fulcrum Therapeutics Inc. (NASDAQ:FULC) shares are up on Thursday as the company faces significant challenges following its decision to discontinue pociredir, its lead experimental drug for sickle cell disease.
Fulcrum Therapeutics stock sinks 51% after ending pociredir development in SCD due to FDA cancer-risk concerns, leaving no clinical-stage assets.
SEC filings reflected insider equity holdings and awards totaling more than 264,000 shares NEW YORK, June 3, 2026 /PRNewswire/ -- Fulcrum Therapeutics, Inc. (NASDAQ: FULC) lost approximately 50% of its value in a single session after disclosing on June 1, 2026, that the FDA had raised class-wide safety concerns about PRC2-targeting agents, leading the Company to discontinue the program of its lead candidate pociredir. Shareholders who lost money on their FULC investment are encouraged to submit their information here.
Fulcrum Therapeutics, Inc. guided investors toward a Phase III future for pociredir while a $25.1 million facility lease locked the company into infrastructure now stranded by program termination. NEW YORK, June 2, 2026 /PRNewswire/ -- Fulcrum Therapeutics, Inc. (NASDAQ: FULC) shareholders saw a roughly 50% single-session collapse after the company disclosed on June 1, 2026 that FDA safety concerns forced immediate discontinuation of pociredir and triggered a strategic review.
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Fulcrum Therapeutics, Inc. (NASDAQ: FULC) or certain of its executive officers violated federal securities laws. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.
ATLANTA, June 02, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Fulcrum Therapeutics, Inc. (“Fulcrum” or the “Company”) (NASDAQ: FULC) complied with federal securities laws. On June 1, 2026, Fulcrum announced the discontinuation of its pociredir program for the treatment of sickle cell disease. The price of the Company's stock dropped following this news.
Shares of Fulcrum Therapeutics plunged 50% in premarket trading on Tuesday after the company said it would abandon development of its experimental sickle-cell disease drug following cancer-risk concerns raised by the U.S. FDA, and explore strategic options including a potential sale or merger.
Fulcrum Therapeutics stock plunged after the company discontinued its lead sickle cell disease drug following FDA concerns.
Fulcrum Therapeutics said on Monday it would stop developing its experimental sickle-cell disease drug after the U.S. Food and Drug Administration raised cancer-risk concerns, which left no viable regulatory path for the treatment.
― Decision follows FDA feedback regarding the implications of the secondary malignancies observed with Tazverik ® (tazemetostat) and the product's subsequent global withdrawal on the benefit-risk profile of pociredir in sickle cell disease (SCD) ―
The heavy selling pressure might have exhausted for Fulcrum Therapeutics (FULC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
CAMBRIDGE, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to two new employees. Fulcrum granted stock options to purchase shares of the company's common stock pursuant to the company's 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employees entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).
Fulcrum Therapeutics, Inc. (FULC) Q1 2026 Earnings Call Transcript
― Presented positive clinical data for pociredir, demonstrating robust and rapid fetal hemoglobin (HbF) induction, improvements in markers of hemolysis and anemia, and encouraging trends in vaso-occlusive crisis (VOC) reduction ―
CAMBRIDGE, Mass. , April 27, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Fulcrum) (NASDAQ: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules that improve the lives of patients with rare hematological disorders, today announced that Josh Lehrer, M. D. , M.
CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules that improve the lives of patients with rare hematological disorders, today announced that Josh Lehrer, M.D., M.Phil., FACC, has been appointed to its Board of Directors as an independent director.
CAMBRIDGE, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its first quarter 2026 financial results will be released on Monday, April 27, 2026, before the U.S. financial markets open.
Fulcrum Therapeutics, Inc. (NASDAQ: FULC - Get Free Report) has received an average rating of "Moderate Buy" from the ten research firms that are presently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the
Three-year collaboration is aimed at enhancing a key aspect of sickle cell management: expediting care during a pain crisis Three-year collaboration is aimed at enhancing a key aspect of sickle cell management: expediting care during a pain crisis
Shares of Fulcrum Therapeutics, Inc. (NASDAQ: FULC - Get Free Report) have earned an average recommendation of "Moderate Buy" from the ten research firms that are covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating
